antibiotic development

ADEP-14 (also known as Acyldepsipeptide-14) is an acyldepsipeptide antibiotic that functions by binding to the ClpP protein, thereby facilitating the degradation of newly synthesized proteins and the FtsZ protein within the cell. This process can potentially lead to cell death, making ADEP-14 a promising compound for development.

Laterocidine is a potent macrolide lipopeptide antibiotic, primarily effective against Gram-negative bacteria including *Pseudomonas aeruginosa* and colistin-resistant *E. coli*. The compound also poses a low risk for the development of antibiotic resistance.

Viquidacin ( NXL-101) is an oral/intravenous antibiotic that targets Gram-positive bacteria such as MRSA. In 2008, Novexel announced it had discontinued the development of Viquidacin (NXL 101).

Deethylindanomycin is a polyether antibiotic that has been found in S. setonii. It is active against a variety of Gram-positive bacteria, including various strains of S. aureus and Streptococcus, as well as one strain of S. pneumoniae (MICs = 4, 4, and 2 μg ml, respectively). It is also active against coccidia in vitro, inhibiting E. tenella development, but is inactive against E. tenella infection in chicks when administered at a dose of 200 μg g in the diet. Deethylindanomycin acts as an ionophore in lipid bilayer membranes and is more selective for potassium ions than calcium, magnesium, and sodium ions. It induces histamine release from rodent mast cells and human basophils in vitro in a calcium-dependent manner.

Anoplin, an antimicrobial peptide found in the venom of the solitary wasp (Anoplius samariensis), exhibits antibacterial activity against a broad spectrum of bacteria, including both Gram-positive and Gram-negative organisms. This compound has potential applications in antibiotic development.

Cyclic L27-11 is a cyclic peptide analog antibiotic that exhibits potent antimicrobial activity against specific bacteria, particularly Pseudomonas sp. It is highly effective against Pseudomonas aeruginosa, demonstrating nanomolar-level antibacterial activity. The mechanism of action for Cyclic L27-11 involves interfering with the function of the bacterial outer membrane protein LptD, inhibiting the normal transport of lipopolysaccharide (LPS). This inhibition leads to the accumulation of membrane-like substances within the bacterial cell, adversely affecting bacterial survival. Consequently, Cyclic L27-11 is a promising candidate for antimicrobial agent development.